A5034896042- interferon and immune responses
- Cytokine Signaling Pathways and Interactions
- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Monoclonal and Polyclonal Antibodies Research
- Cancer Mechanisms and Therapy
- Bacteriophages and microbial interactions
- Immune cells in cancer
- Inflammasome and immune disorders
- Cancer Immunotherapy and Biomarkers
- Virus-based gene therapy research
- Biosimilars and Bioanalytical Methods
- Viral Infectious Diseases and Gene Expression in Insects
TScan Therapeutics (United States)
2022-2023
Takeda (United States)
2022
Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in suppressive microenvironment (TME) remains significant problem. New that activate innate and relieve this suppression may be beneficial overcome hurdle. TAK-676 is synthetic novel stimulator interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate dose-dependently triggers activation STING...
<h3>Background</h3> Adoptive cell transfer with genetically engineered T cells holds great promise for treating solid tumors. To date, clinical investigations of TCR-engineered therapies (TCR-T) have targeted one antigen at a time and produced response rates ranging from 30-50%. Unfortunately, complete responses been rare, are often short-lived. One possible reason why patients rapidly relapse is that their tumors exhibit substantial heterogeneity expression: not every cancer within tumor...
<div><p>Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in suppressive microenvironment (TME) remains significant problem. New that activate innate and relieve this suppression may be beneficial overcome hurdle. TAK-676 is synthetic novel stimulator interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate dose-dependently...
<p>Supplementary methods and results: The supplementary describe: 1) the chemical synthesis characterization of TAK-676, inclusive TAK-676 structure, purification chromatogram NMR characterization; 2) details regarding STING DNA cloning (recombinant E. coli expression utilizing an N-terminal His tag C-terminal Avi tag) for binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description pathway activation (inclusive cell culture methods) in THP1-Dual™,...
<p>Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. 2 mean plasma tumor concentration-time curves TAK-676 in BALB/C mice (A20 syngeneic tumors). 3 percentage body weight change (CT26.WT A20 4 STING-deficient Goldenticket (STING WT B16F10 5 cytokine expression tumor-bearing (plasma tumor).</p>
<div><p>Oncology therapies targeting the immune system have improved patient outcomes across a wide range of tumor types, but resistance due to an inadequate T-cell response in suppressive microenvironment (TME) remains significant problem. New that activate innate and relieve this suppression may be beneficial overcome hurdle. TAK-676 is synthetic novel stimulator interferon genes (STING) agonist designed for intravenous administration. Here we demonstrate dose-dependently...
<p>Supplementary methods and results: The supplementary describe: 1) the chemical synthesis characterization of TAK-676, inclusive TAK-676 structure, purification chromatogram NMR characterization; 2) details regarding STING DNA cloning (recombinant E. coli expression utilizing an N-terminal His tag C-terminal Avi tag) for binding assays (time-resolved fluorescence resonance energy transfer assay); 3) description pathway activation (inclusive cell culture methods) in THP1-Dual™,...
<p>Supplementary figures: Supplementary Figure 1 shows cell viability of human monocyte-derived dendric cells and mouse bone marrow dendritic cells. 2 mean plasma tumor concentration-time curves TAK-676 in BALB/C mice (A20 syngeneic tumors). 3 percentage body weight change (CT26.WT A20 4 STING-deficient Goldenticket (STING WT B16F10 5 cytokine expression tumor-bearing (plasma tumor).</p>
<h3>Background</h3> Engineered T cell therapy holds great promise for treating solid tumors. To date, clinical investigations of TCR-T therapies have targeted one antigen/HLA at a time and produced encouraging but partial response rates with limited durations. While heterogeneity antigen expression is appreciated as likely driver patient relapse, the contribution HLA loss heterozygosity (LOH), occurring in up to 40% tumors, only now gaining attention. address both LOH requires collection...
<h3>Background</h3> Checkpoint immunotherapies have revolutionized solid tumor treatment yet durably benefit a minority of patients, as they rely on endogenous anti-tumor T cells. A potential solution for patients lacking functional cells is engineering their with exogenous cell receptors (TCRs) to target and kill Initial clinical trials TCR engineered therapies (TCR-Ts) produced partial, short-lasting responses because targeted single antigens. Solid tumors are notoriously heterogenous...
<h3>Background</h3> T-Plex is an autologous TCR-T cell therapy product comprising customized combinations of 2–3 components that recognize different tumor antigens presented on specific HLA class I molecules. Each component engineered using a transposon-based vector encoding the therapeutic TCR, CD8α and CD8β co-receptors, CD34 epitope tag, dominant-negative TGFβRII (DN-TGFβRII), mutated form dihydrofolate reductase (DHFRdm). TSC-200-A0201 intended for treatment HPV16+ HLA-A*02:01+ cancers....
<h3>Background</h3> The cancer/testis antigen PRAME exemplifies an ideal TCR-T cell therapy target due to its high expression in multiple malignancies and absence normal tissues. Initially identified metastatic cutaneous melanoma,<sup>1</sup> is highly expressed various additional solid tumors including lung, head & neck, ovarian cancers. plays a pivotal role cellular processes has been demonstrated exhibit protumorigenic function primarily through inhibition of retinoic acid receptor...